Your browser doesn't support javascript.
loading
Dietary fasting and time-restricted eating in Huntington's disease: therapeutic potential and underlying mechanisms.
Wells, Russell G; Neilson, Lee E; McHill, Andrew W; Hiller, Amie L.
Affiliation
  • Wells RG; Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA. wellsru@ohsu.edu.
  • Neilson LE; Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA.
  • McHill AW; Neurology and PADRECC VA Portland Health Care System, Portland, OR, 97239, USA.
  • Hiller AL; Sleep, Chronobiology and Health Laboratory, School of Nursing, Oregon Health & Science University, Portland, OR, 97239, USA.
Transl Neurodegener ; 13(1): 17, 2024 Apr 02.
Article in En | MEDLINE | ID: mdl-38561866
ABSTRACT
Huntington's disease (HD) is a devastating neurodegenerative disorder caused by aggregation of the mutant huntingtin (mHTT) protein, resulting from a CAG repeat expansion in the huntingtin gene HTT. HD is characterized by a variety of debilitating symptoms including involuntary movements, cognitive impairment, and psychiatric disturbances. Despite considerable efforts, effective disease-modifying treatments for HD remain elusive, necessitating exploration of novel therapeutic approaches, including lifestyle modifications that could delay symptom onset and disease progression. Recent studies suggest that time-restricted eating (TRE), a form of intermittent fasting involving daily caloric intake within a limited time window, may hold promise in the treatment of neurodegenerative diseases, including HD. TRE has been shown to improve mitochondrial function, upregulate autophagy, reduce oxidative stress, regulate the sleep-wake cycle, and enhance cognitive function. In this review, we explore the potential therapeutic role of TRE in HD, focusing on its underlying physiological mechanisms. We discuss how TRE might enhance the clearance of mHTT, recover striatal brain-derived neurotrophic factor levels, improve mitochondrial function and stress-response pathways, and synchronize circadian rhythm activity. Understanding these mechanisms is critical for the development of targeted lifestyle interventions to mitigate HD pathology and improve patient outcomes. While the potential benefits of TRE in HD animal models are encouraging, future comprehensive clinical trials will be necessary to evaluate its safety, feasibility, and efficacy in persons with HD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Huntington Disease / Neurodegenerative Diseases Limits: Animals / Humans Language: En Journal: Transl Neurodegener Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Huntington Disease / Neurodegenerative Diseases Limits: Animals / Humans Language: En Journal: Transl Neurodegener Year: 2024 Type: Article Affiliation country: United States